Skip to main content

BLT · NZX

BLIS Technologies (BLT)

Healthcare / BiotechnologyCovered: HY23 - FY268 published briefings

BLIS Technologies is an NZX-listed healthcare / biotechnology company. Its latest covered result is FY26, with HY23 - FY26 of source-backed result history on Annolyse.

Latest result

Latest metrics

FY26, released 21 May 2026

← Swipe to view more
BLT latest metrics
MetricValueChange
Revenue$14.7m↑ +16.0%
NPAT$0.7m↓ -16.5%
Operating cash flow-$0.6m↓ -133.2%
Net debt-$4m—
ROE %5.3%↓ -1.5pp
Annual payout ratio vs EPS %n/m—
PBT$0.8m↓ -10.2%
FCF pre-lease-$1.1m↓ -183.4%
Debtor days51↑ +65.6%
Inventory days40Outside range high inventory days. 40d; 3-period range 21d to 26d. Inventory days: 39.6 days, above normal range; 3-period mean 23.3 days, range 21.0 days-26.2 days.↑ +88.6%

Source: latest published briefing (FY26, released 21 May 2026). Change compares against the prior equivalent period: FY25, released 22 May 2025.

Valuation

Valuation

Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.

Prices as at close, 20 November 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$30.7m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

43.86x

i

Recent market cap compared with trailing earnings.

EPS

0.00

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not meaningful without positive comparable earnings growth.

EV/EBITDA

Not available

i

Not available for this company right now.

P/FCF

Not available

i

Not meaningful when free cash flow is negative or unavailable.

P/B

2.35x

i

Market value compared with latest reported equity.

Income and investment-company measures

Yield and investment-company valuation where supported.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Price history

Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.

Share price

Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.

Loading chart...

P/E over time

Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.

Loading chart...

Ask about BLT

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask company questions.

What changed in the latest result?What is unusual in the historical context?How has cash conversion changed over time?Compare this company with CNU.

Checking account...

Financial history

Performance over time

The latest period is shown first.

← Swipe to view more
BLT metric history
MetricFY2612 MONTHS21 May 2026HY266 MONTHS27 November 2025FY2512 MONTHS22 May 2025HY256 MONTHS26 November 2024FY2412 MONTHS24 May 2024HY246 MONTHS16 November 2023FY2312 MONTHS25 May 2023HY236 MONTHS10 November 2022Trend
Revenue$14.7m$7.7m$12.6m$6m$11.5m$4.8m$10.2m$4.3m
Chart
Revenue growth %16.0%Outside range high revenue growth. 16%; 3-period range 9.7% to 14.2%. Revenue growth: 16.0%, above normal range; 3-period mean 12.2%, range 9.7%-14.2%.28.1%Outside range high revenue growth. 28.1%; 3-period range 10.2% to 25.4%. Revenue growth: 28.1%, above normal range; 3-period mean 15.7%, range 10.2%-25.4%.9.7%25.4%12.6%11.4%14.2%10.2%
Chart
  • HY26 Revenue growth %: Outside range high revenue growth. 28.1%; 3-period range 10.2% to 25.4%. Revenue growth: 28.1%, above normal range; 3-period mean 15.7%, range 10.2%-25.4%.
  • FY26 Revenue growth %: Outside range high revenue growth. 16%; 3-period range 9.7% to 14.2%. Revenue growth: 16.0%, above normal range; 3-period mean 12.2%, range 9.7%-14.2%.
EBITDA—$0.5m$1m—$0.8m———
Chart
EBITDA margin %—6.5%7.9%—6.9%———
Chart
PBT$0.8m$0.44m$0.89m$0.2m$0.7m-$0.7m-$1.3m-$1.7m
Chart
PBT growth %-11.1%78.3%28.0%—————
Chart
NPAT$0.7m$0.42m$0.84m$0.2m$0.6m-$0.7m-$1.3m-$1.7m
Chart
NPAT growth %-12.5%83.0%29.7%—————
Chart
Operating cash flow-$0.6m-$0.49m$1.8m$0.74m$1.1m-$0.04m$0.11m$0.35m
Chart
OCF / EBITDA %—-97.4%178.5%—132.0%———
Chart
FCF pre-lease-$1.1m-$0.8m$1.3m$0.64m$0.49m-$0.12m$0.06m$0.31m
Chart
Annual payout ratio vs EPS %n/m———n/m———
Chart
ROE %5.3%3.3%6.8%2.0%5.6%-6.6%-12.5%-16.1%
Chart
Net debt-$4m————-$3.9m-$4.3m-$8.7m
Chart
Debtor days51—313241385222
Chart
Inventory days40Outside range high inventory days. 40d; 3-period range 21d to 26d. Inventory days: 39.6 days, above normal range; 3-period mean 23.3 days, range 21.0 days-26.2 days.46212523312632
Chart
  • FY26 Inventory days: Outside range high inventory days. 40d; 3-period range 21d to 26d. Inventory days: 39.6 days, above normal range; 3-period mean 23.3 days, range 21.0 days-26.2 days.
Total assets$15m$14.8m$14.3m$13.4m$12.9m$12m$12.8m$12.4m
Chart

Reference: annolyse.ai/companies/blt

Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.

Filing-only history charts

These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.

Revenue

Reported revenue across covered periods.

Loading chart...

Revenue growth

Like-period revenue growth where comparable.

Loading chart...
  • HY26 BLT HY: Outside range high revenue growth. 28.1%; 3-period range 10.2% to 25.4%. Revenue growth: 28.1%, above normal range; 3-period mean 15.7%, range 10.2%-25.4%.
  • FY26 BLT FY: Outside range high revenue growth. 16%; 3-period range 9.7% to 14.2%. Revenue growth: 16.0%, above normal range; 3-period mean 12.2%, range 9.7%-14.2%.

EBITDA-equivalent

Company-specific earnings measure where disclosed.

Loading chart...

EBITDA margin

EBITDA-equivalent margin where revenue and earnings are source-backed.

Loading chart...

NPAT

Statutory profit after tax.

Loading chart...

Operating cash flow

Cash generated from operations.

Loading chart...

More financial metrics

Additional filing-backed metrics for this company. Each point links to the relevant published briefing.

OCF / EBITDA

Cash conversion against earnings.

Loading chart...

FCF pre-lease

Operating cash flow less capex before leases.

Loading chart...

ROE

Return on equity.

Loading chart...

Net debt

Borrowings less cash; negative values indicate net cash.

Loading chart...

Debtor days

Receivables days where the working-capital inputs are source-backed.

Loading chart...

Inventory days

Inventory days where the working-capital inputs are source-backed.

Loading chart...
  • FY26 BLT FY: Outside range high inventory days. 40d; 3-period range 21d to 26d. Inventory days: 39.6 days, above normal range; 3-period mean 23.3 days, range 21.0 days-26.2 days.

Operating working-capital movement

Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.

Loading chart...

The setup & the reality

HY26 → FY26 Follow-through

The latest result is checked against what the prior briefing said to watch.

Historical setup

What HY26 said to watch

Previous analysisHY26Result releasedAnnolyse analysis published

From BLIS grows half-year profit while operating cash turns negative

Management anticipated FY26 revenue growth of10%–15% on FY25. The chair and CEO report describes rounded half-year EBITDA of NZ$0.5m, up NZ$0.2m, and underlying half-year EBITDA of NZ$1.3m excluding one-off costs. The latter is management’s adjusted half-year measure, not an annual run-rate or a new full-year earnings forecast. Management also estimated NZ$0.1m of further supply-chain costs remained to be released.

Open questions

Open questions from HY26

  • How much of the inventory increase is covered by firm customer demand?
  • When will operating cash flow recover after the half-year outflow?
  • How much of the supply-chain cost increase can be avoided in subsequent periods?

Latest result sources

Primary issuer documents used for the FY26 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.

Current period

BLIS Annual Report 2026

FY26 / financial report

Financial Results Announcement

FY26 / results announcement

Financial Results Announcement

FY26 / results release

Prior comparable period

BLIS Annual Report 2025

FY25 / financial report

Financial Results Announcement

FY25 / results announcement

Revenue and earnings growth

FY25 / results release

Interim context

Financial Results Announcement

HY26 / results announcement

Half Year Report 30 September 2025

HY26 / financial report

Strong revenue and underlying earnings growth

HY26 / results release

Release context

BLIS ASM 2025 Presentation slides

HY26 / commentary

Peer context

Other covered Healthcare companies

These companies share a broad sector but may not be direct peers. Compare them only where the underlying measures are genuinely comparable.

Archive

Briefing archive

The full chronological archive contains every published result briefing.

Open all 8 result briefings

Get notified when BLT publishes

Get the next BLIS Technologies result briefing and five-year history updates by email.